Novartis/Glaxo: Chief Digital Officers (CDO) Líderes del cambio

.

The CDO plays a central role in the digital enterprise and therefore in the future success of the business - any business. 

She, or he, must have a multifaceted approach to business, having one eye on the many new IT technologies that are constantly emerging and one eye on how the almost infinite combination of these technologies can transform a business into a digital business.  (Más)

Pharma finally admits “digital is important”

GSK and Novartis have gone to the outside to hire senior digital marketing people with CPG experience. While these moves are long overdue is it enough or is pharma waiting at the airport for their ship to come in? (Más)

August 24, 2017  

GSK and Novartis have just hired execs from the world of retail to be their chief digital officers – with the hope that they can lead transformation in R&D, and relationships with customers. 

Bertrand Bodson

Today Novartis has unveiled Bertrand Bodson as its first ever chief digital officer – a move which illustrates how the role has become one of the most important in pharma. 

Bodson has been poached from his current role as chief digital and marketing officer for Sainsbury’s Argos, the UK supermarket and consumer retail group, and has been hired to extend Novartis’ goal of streamlining its business with technology. 

Novartis’ move reflects gathering momentum in the sector behind major digitally-led change management programmes: big pharma is putting faith in the new efficiencies and streamlining of day-to-day practices that digital technology can bring. 

The digital revolution in data and analytics is already transforming how the industry discovers and develops medicines, and its interactions with patients, consumers and healthcare professionals. 

But the big winners will be those companies that can squeeze the greatest business opportunities out of that revolution, from cutting R&D times to maximising efficiencies and boosting sales. 

Novartis says its new digital chief, who joins on 1 January 2018, will lead projects to improve the way the company uses data in drug discovery and development, engages with patients, doctors and other stakeholders, as well as automating business processes.(...)

Bodson will sit on the management board and report directly to chief executive Joe Jimenez. That’s significant because it gives the new digital supremo real power to lead change across the business, and will undoubtedly be able to set his own targets to save time and money for the company.

Emma Walmsley

GSK’s chief executive Emma Walmsley said Karenann would be given the scope to “think radically about how we can exploit the latest opportunities and ultimately improve our business performance”.

Emma Walmsley ya estuvo en PHARMACOSERÍAS

Ver:

GLAXO tambien "pesca" afuera...

Big Pharma’s Latest Breakthrough: Choosing Its First Female Glaxo CEO Emma Walmsley

Walmsley says GSK will push ahead to find new efficiencies in R&D. This will include more real-time data capture from trials, plus the use of digital to aid trial site selection. 
She points out that the firm has already reduced the time of one trial by six months thanks to better timing of deliveries for trial drugs.(Más)